Total Voting Rights and Block Listing Update

RNS Number : 6160A

ValiRx PLC

01 October 2020

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Total Voting Rights and Block Listing Update

London, UK 1 October 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company today updated its total voting rights disclosure position.

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, the total number of Ordinary Shares in issue will be 63,928,325. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 63,928,325 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

As announced on 29 September 2020, application has been made to the London Stock Exchange to admit the 60,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 2 October 2020.  The new ordinary shares will rank pari passu with the existing ordinary shares.

Following admission of the 60,000 new ordinary shares to trading on AIM on or around 2 October 2020, the Company's total issued share capital will comprise 63,988,325 ordinary shares of 0.1 pence each.

Warrant Update

As at the date of this announcement, 7,930,568 warrants at 13p have been exercised bringing gross proceeds of circa £1,030,000 (of which circa £668,000 were received in September 2020) to the Company and 1,104,164 warrants exercisable at 13p are outstanding.  The aggregate number of warrants exercised at 13p in the month of October 2020 (and subject to the block listing announced on 19 August 2020) will be notified in the monthly total voting rights update on 2 November 2020.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

ValiRx plc Tel: [phone] www.valirx.com Suzanne Dilly [e-mail] Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: [phone] Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker Tel: [phone] Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir Tel: [phone] [e-mail] About ValiRx ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework to enable rapid translation of innovative science into clinical development. With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets. Integrating science and business We connect diverse disciplines across scientific, technical and commercial domains, with the promise of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.  Lead candidates from our portfolio are out-licenced or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

 

END

 

 

TVRFBLFXBKLBBBV